Mga Batayang Estadistika
| LEI | 549300J3MG9F9B5FY646 |
| CIK | 1872529 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MDxHealth SA
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| August 14, 2025 |
Exhibit 99.1 2025 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 5 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 5 2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 6 3. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 7 4 |
|
| August 5, 2025 |
Exhibit 99.1 Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 million Adjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquis |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| July 3, 2025 |
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change Exhibit 99.1 Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will tak |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| June 6, 2025 |
Exhibit 99.2 MDxHealth SA CAP Business Center Rue d’Abhooz, 31 B-4040 Herstal - Belgium E. [email protected] www.mdxhealth.com June 6, 2025 Dear Shareholder, Re: Extraordinary general shareholders’ meeting of MDxHealth SA to be held on June 27, 2025 On behalf of the Board of Directors of MDxHealth SA (the “Company”), you are cordially invited to attend the 2025 extraordinary general shareholders’ |
|
| June 6, 2025 |
Exhibit 99.1 Unofficial English translation – For informational purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) INVITATION extraordinary GENERAL MEETING to be held on Friday, 27 June 2025, at 4:00 p.m. As the quorum for the deliberation |
|
| June 6, 2025 |
Exhibit 99.4 AssemblÉe gÉnÉrale extraordinaire des Actionnaires 27 Juin 2025 extraordinary general shareholders’ meeting 27 June 2025 Procuration Proxy Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial à l’assemblée générale extraordinaire des actionnaires de la Société à tenir le vendredi 27 jui |
|
| June 6, 2025 |
Exhibit 99.3 MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) ATTENDANCE FORM FOR SECURITY HOLDERS Extraordinary General Meeting to be held on Friday, 27 June 2025, at 4:00 p.m. (Belgian time) This attendance form should be used by holders of securitie |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 14, 2025 |
Exhibit 99.2 MDxHealth Reports Q1-2025 Results Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, to |
|
| May 14, 2025 |
Exhibit 99.1 MDxHealth SA and Subsidiaries UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS Three Months Ended March 31, In thousands of $ (except per share amounts) 2025 2024 Revenues $ 24,292 $ 19,834 Cost of sales (exclusive of amortization of intangible assets) (8,788 ) (7,771 ) Gross profit 15,504 12,063 Research and development expenses (2,499 ) (2,164 ) Selling and marketing exp |
|
| May 6, 2025 |
Exhibit 99.1 1. Report of the board of directors This report of the board of directors has been prepared in accordance with the Articles 3:5, 3:6, §1 and 3:32, §1 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the “Belgian Companies and Associations Code” or “BCAC”) and relates to the position of MDxHealth SA, a company domiciled and incorporated in Belgium (the “Com |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 2, 2025 |
Exhibit 99.1 Unofficial English translation – For informational purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) INVITATION ORDINARY and extraordinary GENERAL MEETINGS to be held on Wednesday, 28 May 2025, at 3:00 p.m. The holders of secu |
|
| May 2, 2025 |
Exhibit 99.2 MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) ATTENDANCE FORM FOR SECURITY HOLDERS ordinary and Extraordinary General Meetings to be held on Wednesday, 28 May 2025, at 3:00 p.m. (Belgian time) This attendance form should be used by hold |
|
| May 2, 2025 |
Exhibit 99.5 Free English translation - For information purposes only Free English translation This English version of the 2025 Share Option Plan of MDxHealth SA is a free translation of the original French version. In case of discrepancies between the original French version and this English version, the original French version shall prevail. 2025 SHARE OPTION PLAN MDXHEALTH SA MDxHealth SA ● Rue |
|
| May 2, 2025 |
Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration Exhibit 99.3 AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires 28 mai 2025 ordinary and extraordinary general shareholders’ meetings 28 May 2025 Procuration Proxy Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial aux assemblées générales ordinaire et extraordinaire des actionnaire |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 2, 2025 |
Exhibit 99.4 English translation - For information purposes MDXHEALTH Limited Liability Company CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal Belgium Registered with the Register of Legal Persons VAT BE 0479.292.440 (RLP Liège, division Liège) Report of the Board of Directors in accordance with ARTICLES 7:180 and 7:191 of the Belgian Companies AND ASSOCIATIONS |
|
| March 31, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm MDxHealth SA Herstal, Belgium We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (File No. 333-280606 and 333-268885) of MDxHealth SA of our report dated March 31, 2025 which appears in this Annual Report on Form 20-F. BDO Réviseurs d’Entreprises SRL On behalf of it, /s/ Bert Kegels Za |
|
| March 31, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of MDxHealth SA (the “Company”) for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael K. McGarrity, Chief Executive Officer and Executiv |
|
| March 31, 2025 |
Exhibit 4.15 SEVERANCE AGREEMENT This Severance Agreement (the “Agreement”) is made by and between MDxHealth, Inc., a Delaware corporation (the “Company”), and the undersigned individual (the “Executive”), effective as of November 1, 2024. The Company and the Executive agree as follows: 1. Qualifying Termination. In the event of a Qualifying Termination, the Executive will receive the following pa |
|
| March 31, 2025 |
Insider Trading Policy December 15, 2023 Exhibit 11.1 Insider Trading Policy December 15, 2023 MDxHealth S.A. (the “Company”) has adopted this Insider Trading Policy (as it may be in effect from time to time, this “Policy”) to promote compliance with federal and international securities laws by directors, officers, employees and consultants of the Company and its affiliates, as well as any immediate family members sharing the household o |
|
| March 31, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ron Kalfus, certify that: 1. I have reviewed this annual report on Form 20-F of MDxHealth SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| March 31, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Michael K. McGarrity, certify that: 1. I have reviewed this annual report on Form 20-F of MDxHealth SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact o |
|
| March 31, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of MDxHealth SA (the “Company”) for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ron Kalfus, Chief Financial Officer, certify, pursuant to |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| February 26, 2025 |
Exhibit 99.1 Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “C |
|
| February 13, 2025 |
MXDHF / MDxHealth SA / Bleichroeder LP - SUBSIDIARY INFORMATION (427) Exhibit 99.1 The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E). |
|
| January 13, 2025 |
Exhibit 99.1 MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to repor |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 6, 2024 |
Exhibit 99.2 MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024 Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth |
|
| November 6, 2024 |
CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS Exhibit 99.1 CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS Three Months Ended September 30, Nine Months Ended September 30, Thousands of $ (except per share data) 2024 2023 2024 2023 Revenues 23,317 19,350 65,310 50,795 Cost of sales (exclusive of amortization of intangible assets) (9,042 ) (6,797 ) (25,686 ) (19,537 ) Gross Profit 14,275 12,553 39,624 31,258 Research and developmen |
|
| October 29, 2024 |
Free English translation – for information purposes only Exhibit 3.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT October 29, 2024 Company incorporated by deed given before notary pub |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| October 28, 2024 |
MDXH / MDxHealth SA / MVM Partners, LLC - MVM PARTNERS, LLC FORM SC 13D/A Activist Investment SC 13D/A 1 mvm13da.htm MVM PARTNERS, LLC FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* MDxHealth SA (Name of Issuer) Common Stock (Title of Class of Securities) B5950S113 (CUSIP Number) MVM Partners, LLC Old City Hall 45 School Street Boston, MA 02108 Attn: Eric Bednarski Troutman Pe |
|
| October 4, 2024 |
JOINT FILING AGREEMENT MDxHealth SA EX-99.1 2 exas-20241004xex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT MDxHealth SA In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby confirm the agreement by and among them to the joint filing on behalf of them of the Statement on Schedule 13G and any and all further amendments thereto, with respect to the se |
|
| October 4, 2024 |
MDXH / MDxHealth SA / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MDxHealth SA (Name of Issuer) Ordinary Shares (Title of Class of Securities) B5950S113 (CUSIP Number) September 26, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| October 4, 2024 |
MDXH / MDxHealth SA / Exact Sciences Corp - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) * MDXHEALTH SA (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) B5950S113 (CUSIP Number) September 27, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| October 3, 2024 |
Exhibit 99.1 The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E). |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 25 |
|
| September 30, 2024 |
MDxHealth Announces Launch of Offering of Ordinary Shares Exhibit 99.2 MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40.0 million of ordinary shares of the Company without nominal value (“Ordinary Shares”) in a regist |
|
| September 30, 2024 |
Free English translation – for information purposes only Exhibit 3.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT SEPTEMBER 27, 2024 Company incorporated by deed given before notary p |
|
| September 30, 2024 |
18,500,000 Ordinary Shares MDxHEALTH SA ORDINARY SHARES UNDERWRITING AGREEMENT Exhibit 1.1 18,500,000 Ordinary Shares MDxHEALTH SA ORDINARY SHARES UNDERWRITING AGREEMENT September 25, 2024 TD Securities (USA) LLC William Blair & Company, L.L.C. As Representatives of the several Underwriters c/o TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: 1. Introducto |
|
| September 30, 2024 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 25, 2024, between MDxHealth SA, a limited liability company (naamloze vennootschap/société anonyme) organized under the laws of Belgium (the “Company”), and Genomic Health, Inc., a Delaware corporation (the “Purchaser”). WHEREAS, reference is made to the capital increase within |
|
| September 30, 2024 |
MDxHealth Announces Pricing of Offering of Ordinary Shares Exhibit 99.3 MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value (“Ordinary Shar |
|
| September 26, 2024 |
MDXHEALTH SA 20,000,000 Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No.: 333-268885 PROSPECTUS SUPPLEMENT MDXHEALTH SA 20,000,000 Ordinary Shares We are offering 20,000,000 ordinary shares, no par value (the “ordinary shares”). Our ordinary shares trade on the Nasdaq Capital Market under the symbol “MDXH.” On September 24, 2024, the last sale price of our ordinary shares as reported on the Nasdaq Capital Market was $2. |
|
| September 25, 2024 |
Subject to completion, dated September 25, 2024 MDXHEALTH SA Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No.: 333-268885 The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting offers to buy these securities in any state whe |
|
| August 21, 2024 |
SECOND AMENDMENT TO CREDIT AGREEMENT Exhibit 4.2 Execution Version SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of August 20, 2024 by and among MDX HEALTH, INC., a Delaware corporation (the “Borrower”), MDXHEALTH SA, a limited liability company organized under the laws of Belgium, having its statutory seat at Rue d’Abhooz 31, 4040 Herstal, Belgium and re |
|
| August 21, 2024 |
Exhibit 99.2 MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 million Year-over-year H1 revenues increase by 34% to 42.0 million Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagn |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| August 21, 2024 |
FIRST AMENDMENT TO CREDIT AGREEMENT Exhibit 4.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of July 30, 2024 by and among MDX HEALTH, INC., a Delaware corporation (the “Borrower”), MDXHEALTH SA, a limited liability company organized under the laws of Belgium, having its statutory seat at Rue d’Abhooz 31, 4040 Herstal, Belgium and regist |
|
| August 21, 2024 |
Exhibit 99.1 2024 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 1 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 3 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 3 2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 4 3. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 5 4 |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| July 8, 2024 |
MDxHealth SA Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium MDxHealth SA Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium July 8, 2024 Securities and Exchange Commission 100 F Street, N. |
|
| July 8, 2024 |
MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance Exhibit 99.2 MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary Q2 and half year 2024 revenues and cash. The Company expects to report Q2 and half year 2024 revenues of approximately $2 |
|
| July 8, 2024 |
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors Exhibit 99.1 Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., |
|
| July 3, 2024 |
As filed with the Securities and Exchange Commission on July 3, 2024 As filed with the Securities and Exchange Commission on July 3, 2024 Registration Statement No. |
|
| June 28, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) MDxHealth SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Ordinary Shares, no par value 457(c) 2,243,060 $ 2. |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration Statement No. |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| June 20, 2024 |
Exhibit 1.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 20, 2024, by and among MDXHEALTH SA, a public limited liability company organized under the laws of Belgium, with registered office at Rue d’Abhooz 31, 4040 Herstal (Belgium), registered with the Crossroads Bank for Enterprises under company number 0479.292.440 (the “ |
|
| June 5, 2024 |
Exhibit 99.2 MDxHealth SA CAP Business Center Rue d'Abhooz, 31 B-4040 Herstal - Belgium T. +32 (0) 4 257 70 21 F. +32 (0) 4 259 78 75 June 3, 2024 E. [email protected] www.mdxhealth.com Dear Shareholder, Re: Extraordinary general shareholders' meeting of MDxHealth SA to be held on June 20, 2024 On behalf of the Board of Directors of MDxHealth SA (the “Company”), you are cordially invited to atten |
|
| June 5, 2024 |
Exhibit 99.3 MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) ATTENDANCE FORM FOR SECURITY HOLDERS Extraordinary General Meeting to be held on Thursday, 20 June 2024, at 3:00 p.m. (Belgian time) This attendance form should be used by holders of securit |
|
| June 5, 2024 |
Exhibit 99.1 Unofficial English translation – For informational purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) INVITATION extraordinary GENERAL MEETING to be held on Thursday, 20 June 2024, at 3:00 p.m. As the quorum for the deliberatio |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| June 5, 2024 |
AssemblÉe gÉnÉrale extraordinaire des Actionnaires 20 juin 2024 Exhibit 99.4 AssemblÉe gÉnÉrale extraordinaire des Actionnaires 20 juin 2024 EXTRAordinary general shareholders’ meeting 20 June 2024 Procuration Proxy Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial à l’assemblée générale extraordinaire des actionnaires de la Société à tenir le jeudi 20 juin 2 |
|
| May 16, 2024 |
MDxHealth SA INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.5 MDxHealth SA INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Page Audited Consolidated Financial Statements for the Years Ended December 31, 2023 and 2022 Consolidated Statement of Profit or Loss F-2 Consolidated Statement of Comprehensive Income F-3 Consolidated Statement of Financial Position F-4 Consolidated Statement of Changes in Equity F-5 Consolidated Statement of Cash Flow F-6 |
|
| May 16, 2024 |
Exhibit 99.12 WARRANTS TERMS AND CONDITIONS THE WARRANTS AND THE SECURITIES ISSUABLE UPON EXERCISE OF THE WARRANTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT C |
|
| May 16, 2024 |
Exhibit 99.11 English translation - For information purposes only MDXHEALTH Limited Liability Company CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal Belgium Registered with the Register of Legal Persons VAT BE 0479.292.440 (RLP Liège, division Liège) Report of the Board of Directors in accordance with ARTICLES 7:180, 7:191 and 7:193 of the Belgian Companies AND |
|
| May 16, 2024 |
Exhibit 99.7 English translation - For information purposes only MDXHEALTH Limited Liability Company CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal Belgium Registered with the Register of Legal Persons VAT BE 0479.292.440 (RLP Liège, division Liège) Report of the Board of Directors in accordance with ARTICLES 7:180 and 7:191 of the Belgian Companies AND ASSOCIAT |
|
| May 16, 2024 |
Exhibit 99.9 English translation - For information purposes only MDXHEALTH Limited Liability Company CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal Belgium Registered with the Register of Legal Persons VAT BE 0479.292.440 (RLP Liège, division Liège) Report of the Board of Directors in accordance with ARTICLES 7:180, 7:191 and 7:193 of the Belgian Companies AND A |
|
| May 16, 2024 |
Exhibit 99.3 MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) ATTENDANCE FORM FOR SECURITY HOLDERS ordinary and Extraordinary General Meetings to be held on Thursday, 30 May 2024, at 3:00 p.m. (Belgian time) This attendance form should be used by holde |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 16, 2024 |
Exhibit 99.1 Unofficial English translation – For informational purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) INVITATION ORDINARY and extraordinary GENERAL MEETINGS to be held on Thursday, 30 May 2024, at 3:00 p.m. The holders of secur |
|
| May 16, 2024 |
AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires 30 mai 2024 Exhibit 99.4 AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires 30 mai 2024 ordinary and extraordinary general shareholders’ meetings 30 May 2024 Procuration Proxy Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial aux assemblées générales ordinaire et extraordinaire des actionnaire |
|
| May 16, 2024 |
Exhibit 99.8 Free English translation - For information purposes only Free English translation This English version of the 2024 Share Option Plan of MDxHealth SA is a free translation of the original French version. In case of discrepancies between the original French version and this English version, the original French version shall prevail. 2024 SHARE OPTION PLAN MDXHEALTH SA MDxHealth SA • Rue |
|
| May 16, 2024 |
Exhibit 99.10 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “US SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE RE |
|
| May 16, 2024 |
Exhibit 99.2 MDxHealth SA CAP Business Center Rue d’Abhooz, 31 B-4040 Herstal - Belgium T. +32 (0) 4 257 70 21 F. +32 (0) 4 259 78 75 May 15, 2024 E. [email protected] www.mdxhealth.com Dear Shareholder, Re: Ordinary and extraordinary general shareholders’ meetings of MDxHealth SA to be held on May 30, 2024 On behalf of the Board of Directors of MDxHealth SA (the “Company”), you are cordially inv |
|
| May 16, 2024 |
Exhibit 99.6 1. Report of the board of directors This report of the board of directors has been prepared in accordance with the Articles 3:5, 3:6, §1 and 3:32, §1 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the “Belgian Companies and Associations Code” or “BCAC”) and relates to the position of MDxHealth SA, a company domiciled and incorporated in Belgium (the “Com |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 1, 2024 |
Exhibit 4.2 Execution Version PLEDGE AND SECURITY AGREEMENT This PLEDGE AND SECURITY AGREEMENT, dated as of May 1, 2024 (as amended, supplemented or otherwise modified from time to time, this “Security Agreement”), is made by MDXHEALTH, INC., a Delaware corporation (the “Borrower”), and the other entities listed on Annex A hereto (together with the Borrower and any other entity that may become par |
|
| May 1, 2024 |
MDxHealth SA ORDINARY SHARES SALES AGREEMENT Exhibit 1.1 MDxHealth SA $50,000,000 ORDINARY SHARES SALES AGREEMENT April 30, 2024 TD Securities (USA) LLC (dba TD Cowen) 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: MDxHealth SA, a limited liability company (naamloze vennootschap/société anonyme) organized under the laws of Belgium (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 1, 2024 |
Exhibit 99.1 MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 million Increasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdx |
|
| May 1, 2024 |
Exhibit 4.1 CREDIT AGREEMENT dated as of May 1, 2024 by and among MDXHEALTH, INC., as the Borrower, MDXHEALTH SA, as Parent, ORC SPV LLC, as the Initial Lender, and ORC SPV LLC, as the Administrative Agent TABLE OF CONTENTS Page Article I DEFINITIONS AND ACCOUNTING TERMS 1 SECTION 1.1 Defined Terms. 1 SECTION 1.2 Use of Defined Terms 24 SECTION 1.3 Cross-References 24 SECTION 1.4 Accounting and Fi |
|
| May 1, 2024 |
Exhibit 99.1 MDxHealth SA and Subsidiaries UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS Three Months Ended March 31, In thousands of $ (except per share amounts) 2024 2023 Revenues $ 19,834 $ 14,700 Cost of sales (exclusive of amortization of intangible assets) (7,771 ) (5,985 ) Gross profit 12,063 8,715 Research and development expenses (2,164 ) (1,316 ) Selling and marketing expe |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 1, 2024 |
Exhibit 4.3 WARRANTS TERMS AND CONDITIONS THE WARRANTS AND THE SECURITIES ISSUABLE UPON EXERCISE OF THE WARRANTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COV |
|
| April 30, 2024 |
SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT Exhibit 4.24 Execution version SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT This SECOND AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”), dated as of August 23, 2023, is entered into between Genomic Health, Inc., a Delaware corporation (“GHI” or “Seller”), and MDxHealth SA a limited liability company (société anonyme) organized and existing under the laws of Belgium (“MDx” or “Buyer”). Cap |
|
| April 30, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Michael K. McGarrity, certify that: 1. I have reviewed this annual report on Form 20-F of MDxHealth SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact o |
|
| April 30, 2024 |
MDXHEALTH SA Up to $50,000,000 Ordinary Shares 424B5 1 ea0204694-01.htm PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No.: 333-268885 PROSPECTUS SUPPLEMENT (To Prospectus dated December 19, 2022) MDXHEALTH SA Up to $50,000,000 Ordinary Shares We have entered into a sales agreement with TD Securities (USA) LLC (“TD Cowen”), dated April 30, 2024, relating to the sale of our ordinary shares, no par value, offered by this prospectus sup |
|
| April 30, 2024 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares and the articles of association of MDxHealth SA (“MDxHealth”, the “Company” or “we,” “our,” or “us”) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety by reference to, the complete t |
|
| April 30, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of MDxHealth SA (the “Company”) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael K. McGarrity, Chief Executive Officer and Executiv |
|
| April 30, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM MDxHealth SA Herstal, Belgium We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 30, 2024 included in this Form 20-F in the Registration Statement (Form F-3, File No. 333-268885). BDO Réviseurs d’Entreprises SRL On behalf of it, /s/ Bert Kegels Zaventem, Belgium April 30, |
|
| April 30, 2024 |
Incentive-BASED Compensation Recovery Policy Exhibit 97 Incentive-BASED Compensation Recovery Policy 1. Policy Purpose. The purpose of this MDxHealth SA (the “Company”) Incentive-Based Compensation Recovery Policy (this “Policy”) is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to comply with the requirements set forth |
|
| April 30, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ron Kalfus, certify that: 1. I have reviewed this annual report on Form 20-F of MDxHealth SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| April 30, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of MDxHealth SA (the “Company”) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ron Kalfus, Chief Financial Officer, certify, pursuant to |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| March 12, 2024 |
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering Exhibit 99.1 Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostic company, announces the introduction of a non-invasive genetic prostate cancer test through its urology sales channel. With a simple sali |
|
| March 6, 2024 |
Exhibit 99.1 Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “ |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| February 16, 2024 |
Mdxhealth Announces Resignation of Board Member Exhibit 99.1 Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensae |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| February 14, 2024 |
MXDHF / MDxHealth SA / Bleichroeder LP Passive Investment SC 13G/A 1 mdxhealthsa13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) MDxHealth SA (Name of Issuer) Common Shares (Title of Class of Securities) 58286E102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 8, 2024 |
Exhibit 99.1 MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today reported preliminary fourth quarter and full year 2023 revenues and issued 2024 revenue guidance. The Company expects to report |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| December 19, 2023 |
Free English translation – for information purposes only Exhibit 3.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT December 15, 2023 Company incorporated by deed given before notary pu |
|
| December 19, 2023 |
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq Exhibit 99.1 NEWS RELEASE – REGULATED INFORMATION DECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – December 18, 2023 – MDxHealth SA (Nasdaq: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today announces the completion of its transition to a single listin |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 27, 2023 |
Exhibit 99.1 NEWS RELEASE – REGULATED INFORMATION NOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – November 27, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 MDXHEALTH SA (Exact name of registrant as specified in its charter) Belgium Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) CAP |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 15, 2023 |
Free English translation – for information purposes only Exhibit 3.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT November 13, 2023 Company incorporated by deed given before notary pu |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 13, 2023 |
Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION INSIDE INFORMATION NOVEMBER 13, 2023, 4:00 PM ET / 22:00 CET MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights IRVINE, CA, and HERSTAL, BELGIUM – November 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today ann |
|
| November 8, 2023 |
Free English translation – for information purposes only Exhibit 3.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT November 3, 2023 Company incorporated by deed given before notary pub |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 8, 2023 |
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 Exhibit 99.1 NEWS RELEASE – REGULATED INFORMATION 8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 IRVINE, CA, and HERSTAL, BELGIUM – November 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarter and nine-mont |
|
| November 8, 2023 |
Exhibit 99.2 MDxHealth SA and Subsidiaries UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME Three Months Ended September 30, Nine Months Ended September 30, In thousands of $ (except per share amounts) 2023 2022 2023 2022 Services 19,340 11,136 50,685 24,111 Royalties and other revenues 10 18 110 52 Revenues 19,350 11,154 50,795 24,163 Cost of goods & services |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 6, 2023 |
Exhibit 99.1 NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION NOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation IRVINE, CA, and HERSTAL, BELGIUM – November 6, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a |
|
| October 23, 2023 |
Mdxhealth’s New Share Capital Amount and New Number of Shares Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION October 20, 2023, 4:00 PM EDT / 22:00 CET Mdxhealth’s New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM – October 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of Ma |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| October 11, 2023 |
Exhibit 99.1 |
|
| October 11, 2023 |
Exhibit 99.2 Notice of The Bank of New York Mellon, as Depositary, of Extraordinary Shareholders’ Meeting of MDxHeath SA to be held on November 3, 2023 Only those Holders of ADSs of record on October 4, 2023 (the “ADS Record Date”) and October 20, 2023 (the “Share Record Date”) are entitled to vote at the Meeting A Holder of American Depositary Shares (“ADSs”) may instruct The Bank of New York Mel |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| October 10, 2023 |
MDxHealth Reports Preliminary Q3-2023 Revenues Exhibit 99.1 NEWS RELEASE – INSIDE AND REGULATED INFORMATION 9 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary Q3-2023 Revenues IRVINE, CA, and HERSTAL, BELGIUM – October 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary third quarter 2023 revenues, units, and cash position. For the third quarter ended Septem |
|
| October 3, 2023 |
Exhibit 99.5 Published 2 Oct 2023 FAQs REGARDING THE SHARE CONSOLIDATION, TERMINATION OF THE ADS PROGRAM AND EURONEXT DE-LISTING FOR REPOSITIONING ON NASDAQ Set forth below are frequently asked questions (FAQs) relating to the proposed share consolidation, the termination of the ADS program, the Euronext de-listing and (subject to the approval of the proposed share consolidation and de-listing) th |
|
| October 3, 2023 |
Exhibit 99.4 LETTER FROM THE CHAIRPERSON MDXHEALTH SA (a company with limited liability (naamloze vennootschap/société anonyme) incorporated and operating under the laws of Belgium, with enterprise number 0479.292.440) October 2, 2023 To the Holders of Shares Dear Shareholders: Proposed share consolidation, termination of the ADS program and Euronext de-listing for repositioning on Nasdaq Overview |
|
| October 3, 2023 |
Exhibit 99.6 Unofficial English translation – For informational purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) INVITATION extraordinary GENERAL MEETING to be held on Friday, 3 November 2023, at 3:00 p.m. The holders of securities issued |
|
| October 3, 2023 |
Exhibit 99.2 NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION OCTOBER 2, 2023, 4:00pm ET / 22:00 CET MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting IRVINE, CA, and HERSTAL, BELGIUM – October 2, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage preci |
|
| October 3, 2023 |
Exhibit 99.10 Free English translation for information purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) Outstanding Shares and voting rights extraordinary general shareholders’ MEETING to be held on Friday, 3 November 2023, at 3:00 p.m. T |
|
| October 3, 2023 |
Exhibit 99.3 MDxHealth SA CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium Special Report regarding the Proposed Share Consolidation and De-Listing of Shares from the Regulated Market of Euronext Brussels This special report (the “Special Report”) has been prepared by the board of directors of MDxHealth SA, a limited liability company organized under the laws of Belgium, |
|
| October 3, 2023 |
AssemblÉe gÉnÉrale extraordinaire des Actionnaires 3 NOVEMBRE 2023 Exhibit 99.9 AssemblÉe gÉnÉrale extraordinaire des Actionnaires 3 NOVEMBRE 2023 extraordinary general shareholders’ meeting 3 November 2023 formulaire de vote par correspondance Voting by mail form Ce formulaire doit être utilisé par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent voter par correspondance à l’assemblée générale extraordinaire des actionnaires de la Société à t |
|
| October 3, 2023 |
AssemblÉe gÉnÉrale extraordinaire des Actionnaires 3 novembre 2023 Exhibit 99.8 AssemblÉe gÉnÉrale extraordinaire des Actionnaires 3 novembre 2023 extraordinary general shareholders’ meeting 3 NOVEMBER 2023 Procuration Proxy Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial à l’assemblée générale extraordinaire des actionnaires de la Société à tenir le vendredi |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| October 3, 2023 |
Exhibit 99.1 NEWS RELEASE September 26, 2023, 4:00PM EDT / 22:00 CET Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM – September 26, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostic |
|
| October 3, 2023 |
Exhibit 99.7 MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) ATTENDANCE FORM FOR SECURITY HOLDERS Extraordinary General Meeting to be held on Friday, 3 November 2023, at 3:00 p.m. (Belgian time) This attendance form should be used by holders of securi |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| August 23, 2023 |
Exhibit 99.1 2023 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 4 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 4 2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 5 3. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 6 4 |
|
| August 23, 2023 |
MDxHealth Reports Q2 and Half Year 2023 Results Exhibit 99.2 NEWS RELEASE – REGULATED INFORMATION 23 AUGUST 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q2 and Half Year 2023 Results ● Year-over-year Q2 revenues increase by 143% to $16.7 million; excluding GPS, revenues up 29% ● Q2 gross margin expanded to 59.7% up from 42.4% in the prior year period ● Amended GPS purchase agreement with Exact Sciences defers Company’s earn-out payment period |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| August 10, 2023 |
Exhibit 99.1 NEWS RELEASE 9 AUGUST 2023, 4PM ET / 22:00 CET Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test Expansion of coverage with Cigna now includes full menu of Company’s precision diagnostic prostate cancer tests, representing more than 15 million lives under coverage IRVINE, CA, and HERSTAL, BELGIUM – August 9, 2023 – MDxH |
|
| July 5, 2023 |
Free English translation – for information purposes only Exhibit 1.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT JUNE 30, 2023 Company incorporated by deed given before notary public |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| July 3, 2023 |
MDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION 30 June 2023, 10:00 p.m. CEST MDxHealth Announces Results of its Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – 30 June 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today held an extraordinary general shareholders’ meeting ( |
|
| June 6, 2023 |
Exhibit 99.5 Free English translation for information purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) OUTSTANDING SHARES AND VOTING RIGHTS EXTRAORDINARY GENERAL SHAREHOLDERS’ MEETING to be held on Friday, 30 June 2023, at 9:00 a.m. This |
|
| June 6, 2023 |
Exhibit 99.1 Unofficial English translation – For informational purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) INVITATION EXTRAORDINARY GENERAL MEETING to be held on Friday, 30 June 2023, at 9:00 a.m. As the quorum for the deliberation |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| June 6, 2023 |
MDxHealth Announces its Extraordinary General Shareholders’ Meeting Exhibit 99.6 NEWS RELEASE – REGULATED INFORMATION JUNE 5, 2023, 5:30 pm ET/ 23:30 CEST MDxHealth Announces its Extraordinary General Shareholders’ Meeting IRVINE, CA, and HERSTAL, BELGIUM – June 5, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company t |
|
| June 6, 2023 |
AssemblÉe gÉnÉrale extraordinaire des Actionnaires 30 juin 2023 Exhibit 99.4 AssemblÉe gÉnÉrale extraordinaire des Actionnaires 30 juin 2023 extraordinary general shareholders’ meeting 30 June 2023 formulaire de vote par correspondance Voting by mail form Ce formulaire doit être utilisé par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent voter par correspondance à l’assemblée générale extraordinaire des actionnaires de la Société à tenir l |
|
| June 6, 2023 |
AssemblÉe gÉnÉrale extraordinaire des Actionnaires 30 Juin 2023 Exhibit 99.3 AssemblÉe gÉnÉrale extraordinaire des Actionnaires 30 Juin 2023 extraordinary general shareholders’ meeting 30 June 2023 Procuration Proxy Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial à l’assemblée générale extraordinaire des actionnaires de la Société à tenir le vendredi 30 jui |
|
| June 6, 2023 |
Exhibit 99.2 MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) ATTENDANCE FORM FOR SECURITY HOLDERS Extraordinary General Meeting to be held on Friday, 30 June 2023, at 9:00 a.m. (Belgian time) This attendance form should be used by holders of securitie |
|
| May 26, 2023 |
MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION 25 May 2023, 22:30 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders’ Meetings IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (“MDxHealth” or the “Company”), a commercial-stage precision diagnostics company, today held its ordinary annual general shareholders’ me |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 15, 2023 |
MDxHealth Reports Q1-2023 Results Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION 15 MAY 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Q1-2023 Results § Year-over-year revenues increase by 141% to $14.7 million; excluding GPS, revenues up 39% § Gross margin expanded by 1,270 basis points over prior year period § Positive Local Coverage Determination (LCD), extending coverage for Select mdx test to Medicare population IRVINE, CA |
|
| May 15, 2023 |
Exhibit 99.2 MDxHealth SA and Subsidiaries UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME Three Months Ended March 31, In thousands of $ (except per share amounts) 2023 2022 Services 14,607 6,092 Royalties and other revenues 93 14 Revenues 14,700 6,106 Cost of goods & services sold (5,985 ) (3,263 ) Gross profit 8,715 2,843 Research and development expenses ( |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| April 26, 2023 |
Exhibit 99.5 Free English translation for information purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) Outstanding Shares and voting rights ORDINARY and extraordinary general shareholders’ MEETINGs to be held on Thursday, 25 May 2023, at |
|
| April 26, 2023 |
MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings Exhibit 99.10 NEWS RELEASE – REGULATED INFORMATION APRIL 25, 2023, 4:00 pm ET/ 22:00 CET MDxHealth Announces its Ordinary and Extraordinary General Shareholders’ Meetings IRVINE, CA, and HERSTAL, BELGIUM – April 25, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today invites the holders of securities issue |
|
| April 26, 2023 |
Office (EU Headquarters) CAP Business Center Rue d’Abhooz 31 4040 Hertsal Office and Laboratory (US Headquarters) 15279 Alton Parkway Suite 100 Irvine, CA 92618 Laboratory 7000 Preston Road Suite. |
|
| April 26, 2023 |
Exhibit 99.2 MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) ATTENDANCE FORM FOR SECURITY HOLDERS ordinary and Extraordinary General Meetings to be held on Thursday, 25 May 2023, at 15:00 p.m. (Belgian time) This attendance form should be used by hold |
|
| April 26, 2023 |
Exhibit 99.8 Free English translation - For information purposes only Free English translation This English version of the 2023 Share Option Plan of MDxHealth SA is a free translation of the original French version. In case of discrepancies between the original French version and this English version, the original French version shall prevail. 2023 SHARE OPTION PLAN MDXHEALTH SA MDxHealth SA • Rue |
|
| April 26, 2023 |
Exhibit 99.1 Unofficial English translation – For informational purposes only MDxHealth SA Limited Liability Company (société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal, Belgium VAT BE 0479.292.440 (RLP Liège, division Liège) INVITATION ORDINARY and extraordinary GENERAL MEETINGS to be held on Thursday, 25 May 2023, at 3:00 p.m. The holders of secur |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| April 26, 2023 |
AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires 25 mai 2023 Exhibit 99.3 AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires 25 mai 2023 ordinary and extraordinary general shareholders’ meetings 25 May 2023 Procuration Proxy Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial aux assemblées générales ordinaire et extraordinaire des actionnaire |
|
| April 26, 2023 |
AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires 25 mai 2023 Exhibit 99.4 AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires 25 mai 2023 ordinary and extraordinary general shareholders’ meetings 25 May 2023 formulaire de vote par correspondance Voting by mail form Ce formulaire doit être utilisé par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent voter par correspondance aux assemblées générales ordinaire et extraordinair |
|
| April 26, 2023 |
Exhibit 99.7 English translation - For information purposes only MDXHEALTH Limited Liability Company CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal Belgium Registered with the Register of Legal Persons VAT BE 0479.292.440 (RLP Liège, division Liège) Report of the Board of Directors in accordance with ARTICLES 7:180 and 7:191 of the Belgian Companies AND ASSOCIAT |
|
| April 26, 2023 |
Exhibit 99.9 ***Unofficial English translation - For information purposes only *** MDXHEALTH Limited Liability Company (Société anonyme) CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31 4040 Herstal Belgium Registered with the Register of Legal Persons VAT BE 0479.292.440 (RLP Liège, Section Liège) SPECIAL Report of the Board of Directors in accordance with Article 7:199 OF th |
|
| April 25, 2023 |
DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the ordinary shares, the American Depositary Shares and the articles of association of MDxHealth SA (“MDxHealth”, the “Company” or “we,” “our,” or “us”) is a summary and does not purport to be complete. This summary is subject to, and qualified in its entirety |
|
| April 25, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ron Kalfus, certify that: 1. I have reviewed this annual report on Form 20-F of MDxHealth SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to |
|
| April 25, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM MDxHealth SA Herstal, Belgium We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 25, 2023 included in this Form 20-F in the Registration Statement (Form F-3, File No. 333-268885). BDO Réviseurs d’Entreprises SRL On behalf of it, /s/ Bert Kegels Zaventem, Belgium April 25, |
|
| April 25, 2023 |
Exhibit 4.15 CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “Agreement”) dated as of August 2, 2022 (the “Ef |
|
| April 25, 2023 |
AMENDMENT TO ASSET PURCHASE AGREEMENT Exhibit 4.17 CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Execution Copy AMENDMENT TO ASSET PURCHASE AGREEMENT This AMENDMENT TO ASSET PURCHASE AGREEMENT (this “Amendment”), dated as of January 1, 2023, is entered into between Genomic Health, Inc., a Delaw |
|
| April 25, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Michael K. McGarrity, certify that: 1. I have reviewed this annual report on Form 20-F of MDxHealth SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact o |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 25, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of MDxHealth SA (the “Company”) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael K. McGarrity, Chief Executive Officer and Executiv |
|
| April 25, 2023 |
Exhibit 4.16 CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. ASSET PURCHASE AGREEMENT between GENOMIC HEALTH, INC. and MDXHEALTH SA dated as of August 2, 2022 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”), dated as of August 2, 202 |
|
| April 25, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of MDxHealth SA (the “Company”) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ron Kalfus, Chief Financial Officer, certify, pursuant to |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| April 20, 2023 |
Foundational LCD Covers Select mdx® for Prostate Cancer Exhibit 99.1 NEWS RELEASE – INSIDE INFORMATION April 19, 2023, 4:00PM EDT / 22:00 CET Foundational LCD Covers Select mdx® for Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM – April 19, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, received notice that its Select mdx for Prostate Cancer test has successfully completed a rigorous technical assessmen |
|
| April 14, 2023 |
MXDHF / MDxHealth SA / TopMDx Ltd. - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D / A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MDxHealth SA (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) 58286E102 ** (CUSIP Number) Richard Bray Valiance Asset Management Limited 1st Floor, Tudor House Le Bordage, St. Peter Port, Guernsey GY 1DB +44 207 399 1770 |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 |
|
| April 14, 2023 |
MDxHealth Shareholder Transparency Declaration Exhibit 99.1 NEWS RELEASE – REGULATED INFORMATION APRIL 7, 2023, 4:30 pm ET/ 22:30 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM – April 7, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of May 2, 2007 on |
|
| March 17, 2023 |
MXDHF / MDxHealth SA / Biovest NV - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 9, 2023 |
Exhibit 99.5 MDxHealth SA and Subsidiaries 2022 Financial Results as of and for the year ended December 31, 2022 Unaudited consolidated statement of profit or loss Thousands of $ (except per share amounts) For the years ended December 31 2022 2021 Services 36,965 21,937 Licenses 25 250 Royalties and other revenues 64 52 Revenues 37,054 22,239 Cost of goods & services sold (17,835 ) (11,675 ) Gross |
|
| March 9, 2023 |
6-K 1 ea174883-6kmdxhealth.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone |
|
| March 9, 2023 |
Exhibit 99.3 NEWS RELEASE - REGULATED INFORMATION 8 MARCH 2023, 4:00 PM EST / 22:00 CET MDxHealth Reports Financial Year 2022 Results and Provides Business Update and Outlook for 2023 Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision |
|
| March 9, 2023 |
MDxHealth Shareholder Transparency Declarations Exhibit 99.1 NEWS RELEASE – REGULATED INFORMATION MARCH 2, 2023, 4:30 pm ET/ 22:30 CET MDxHealth Shareholder Transparency Declarations IRVINE, CA, and HERSTAL, BELGIUM – March [2], 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 2007 o |
|
| March 9, 2023 |
Free English translation – for information purposes only Exhibit 3.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT MARCH 8, 2023 Company incorporated by deed given before notary public |
|
| March 9, 2023 |
MDxHealth Announces Exercise of Option Exhibit 99.2 NEWS RELEASE – REGULATED INFORMATION MARCH 6, 2023, 5:30 pm ET/ 23:30 CET MDxHealth Announces Exercise of Option IRVINE, CA, and HERSTAL, BELGIUM – March 6, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced that, in the context of the registered public offering of 10,000,000 American Depositary |
|
| March 9, 2023 |
MDxHealth Announces Update of Outstanding Shares and Voting Rights Exhibit 99.4 NEWS RELEASE – REGULATED INFORMATION MARCH 8, 2023, 5:00 pm ET/ 23:00 CET MDxHealth Announces Update of Outstanding Shares and Voting Rights IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, |
|
| February 28, 2023 |
MXDHF / MDxHealth SA / MVM Partners, LLC - MVM PARTNERS, LLC FORM SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* MDxHealth SA (Name of Issuer) Common Stock (Title of Class of Securities) 58286E102 ** (CUSIP Number) MVM Partners, LLC Old City Hall 45 School Street Boston, MA 02108 Attn: Eric Bednarski Troutman Pepper Hamilton Sanders LLP 400 Berwyn Park 899 Cassat |
|
| February 23, 2023 |
MDxHealth Shareholder Transparency Declaration Exhibit 99.1 NEWS RELEASE – REGULATED INFORMATION FEBRUARY 21, 2023, 4:30 pm ET/ 22:30 CET MDxHealth Shareholder Transparency Declaration IRVINE, CA, and HERSTAL, BELGIUM – 21 February 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, announces today in accordance with Article 14 of the Belgian Act of 2 May 20 |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| February 15, 2023 |
Exhibit 99.1 NEWS RELEASE 13 FEBRUARY 2023, 4:00PM ET / 22:00 CET MDxHealth Announces UnitedHealthcare to Provide Commercial Coverage for the Genomic Prostate Score (GPS) Test UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men newly diagnosed with localized prostate cancer IRVINE, CA, and HERSTAL, BELGIUM – February 13, 2023 – MDxHealth SA ( |
|
| February 15, 2023 |
MDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar EX-99.2 3 ea173435ex99-2mdxhealth.htm PRESS RELEASE, DATED FEBRUARY 15, 2023 Exhibit 99.2 NEWS RELEASE – REGULATED INFORMATION FEBRUARY 15, 2023, 4:30 pm ET/ 22:30 CET MDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commer |
|
| February 15, 2023 |
6-K 1 ea173435-6kmdxhealth.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Z |
|
| February 14, 2023 |
MXDHF / MDXHealth SA / Bleichroeder LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) MDxHealth SA (Name of Issuer) Common Shares (Title of Class of Securities) 58286E102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 9, 2023 |
MDxHealth Announces Pricing of Offering of ADSs in the United States Exhibit 99.2 NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 3, 2023, 8:00 am ET/ 14:00 CET MDxHealth Announces Pricing of Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM – February 3, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced that it has priced a registered p |
|
| February 9, 2023 |
6-K 1 ea172748-6kmdxhealth.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Z |
|
| February 9, 2023 |
MDxHealth Announces Launch of Offering of ADSs in the United States Exhibit 99.1 NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION FEBRUARY 1, 2023, 4PM ET/ 22:00 CET MDxHealth Announces Launch of Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM –February 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40,000, |
|
| February 9, 2023 |
Free English translation – for information purposes only Exhibit 3.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT FEBRUARY 7, 2023 Company incorporated by deed given before notary pub |
|
| February 9, 2023 |
Exhibit 1.1 10,000,000 American Depositary Shares MDxHEALTH SA AMERICAN DEPOSITARY SHARES EACH REPRESENTING TEN (10) ORDINARY SHARES UNDERWRITING AGREEMENT February 3, 2023 Cowen and Company, LLC William Blair & Company, L.L.C. As Representatives of the several Underwriters c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 William Blair & Company, L.L.C. 150 N. Riverside Pla |
|
| February 6, 2023 |
MDXHEALTH SA 10,000,000 American Depositary Shares Representing Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No.: 333-268885 PROSPECTUS SUPPLEMENT MDXHEALTH SA 10,000,000 American Depositary Shares Representing Ordinary Shares We are offering 10,000,000 of our American Depositary Shares (“ADSs”), each of which represents ten ordinary shares. Our ADSs trade on the Nasdaq Capital Market under the symbol “MDXH.” On February 2, 2023, the last sale price of our AD |
|
| February 1, 2023 |
424B5 1 f424b50123mdxhealthsa.htm PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No.: 333-268885 The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting of |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| January 20, 2023 |
MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test Exhibit 99.1 NEWS RELEASE –REGULATED INFORMATION 20 JANUARY 2023, 1:00 am ET / 7:00 am CET MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test IRVINE, CA, and HERSTAL, BELGIUM – January 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided supplemental information related to its acquisition |
|
| January 20, 2023 |
INTERIM REPORT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 Exhibit 99.2 INTERIM REPORT FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2022 TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT F-2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA F-3 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME F-3 2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION F-4 3. CONDENSED UNAUDITED |
|
| January 20, 2023 |
Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2022, AND FOR THE YEAR ENDED DECEMBER 31, 2021 Unaudited Pro Forma Financial Information On August 2, 2022, MDxHealth SA (“mdxhealth” or the “Company”) entered into an asset purchase agreement (the “Acquisition”) with Genomic Health, Inc., a subsidiary of Exact Sciences Corporation (“Exact S |
|
| January 9, 2023 |
MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance Exhibit 99.1 NEWS RELEASE – INSIDE AND REGULATED INFORMATION 9 JANUARY 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary 2022 revenues and reaffirmed its 2023 revenue guidance. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| December 28, 2022 |
December 28, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jordan Nimitz Re: MDxHealth SA Registration Statement on Form F-3 File No. 333-268885 Acceleration Request Requested Date: December 30, 2022 Requested Time: 4:30 p.m., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Ac |
|
| December 19, 2022 |
Report of Independent Auditors Exhibit 99.1 Report of Independent Auditors To the Management of Exact Sciences Corporation Opinion We have audited the accompanying special purpose combined financial statements of the Oncotype DX Prostate Score® Test (“GPS”), a diagnostic test offered by Exact Sciences Corporation, which comprises the special purpose combined statements of assets acquired and liabilities assumed as of December 3 |
|
| December 19, 2022 |
As filed with the Securities and Exchange Commission on December 19, 2022 F-3 1 ea170214-f3mdxhealthsa.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on December 19, 2022 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MDXHEALTH SA (Exact name of Registrant as specified in its charter) Belgium Not Applicable (State or |
|
| December 19, 2022 |
EX-99.2 3 ea170279ex99-2mdxhealth.htm UNAUDITED PRO FORMA CONDENSED CONSOLIDATED COMBINED BALANCE SHEETS OF THE COMPANY AND ONCOTYPE DX PROSTATE SCORE TEST AS OF DECEMBER 31, 2020, DECEMBER 31, 2021 AND JUNE 30, 2022 Exhibit 99.2 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2022, AND FOR THE YEAR ENDED DECEMBER 31, 2021 Unaudited Pro Forma Financia |
|
| December 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables ……Form F-3…….. (Form Type) …………….…………… MDxHealth SA ………………………….. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(2)(3) Maximum Aggregate Offering Price(2)( |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant?s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| November 29, 2022 |
MDxHealth Provides Business Update Exhibit 99.1 NEWS RELEASE ? INSIDE AND REGULATED INFORMATION 29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM ? November 29, 2022 ? MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided clinical and reimbursement product developments, updated guidance for 2022, and initial guidance for 2023 |
|
| November 23, 2022 |
MXDHF / MDXHealth SA / MVM Partners, LLC - MVM PARTNERS LLC FORM SC 13D/A MDXH Activist Investment SC 13D/A 1 mvmsc13da.htm MVM PARTNERS LLC FORM SC 13D/A MDXH UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MDxHealth SA (Name of Issuer) Common Stock (Title of Class of Securities) 58286E102 ** (CUSIP Number) MVM Partners, LLC Old City Hall 45 School Street Boston, MA 02108 Attn: Eric Bednarski Tr |
|
| November 23, 2022 |
AMENDED AND RESTATED JOINT FILING AGREEMENT Exhibit 1 AMENDED AND RESTATED JOINT FILING AGREEMENT The undersigned acknowledge and agree that the statement on Schedule 13D with respect to the beneficial ownership by the undersigned of the ordinary shares, no par value, of MDxHealth SA, to which this Joint Filing Agreement is filed as an exhibit, has been filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements, in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934. |
|
| October 27, 2022 |
MDxHealth Reports Q3-2022 Results EX-99.1 2 ea167615ex99-1mdxhealth.htm PRESS RELEASE, DATED OCTOBER 27, 2022 Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION 27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – October 27, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarte |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 |
|
| August 26, 2022 |
EX-99.1 2 ea164904ex99-1mdxhealth.htm 2022 INTERIM REPORT Exhibit 99.1 2022 INTERIM REPORT TABLE OF CONTENTS I. INTERIM MANAGEMENT REPORT 2 II. INTERIM CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MDXHEALTH SA 3 1. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 3 2. CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION 4 3. CONDENSED |
|
| August 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant?s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant?s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| August 25, 2022 |
MDxHealth Reports Half Year 2022 Results Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION 25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM – August 25, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company”), a commercial-stage precision diagnostics company, today announced its financial results for the half year ended June 30, 2022. Michael K. McGarrity, |
|
| August 19, 2022 |
Mdxhealth’s New Share Capital Amount and New Number of Shares Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION August 19, 2022, 4:00 PM EDT / 22:00 CET Mdxhealth?s New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM ? August 19, 2022 ? MDxHealth SA (NASDAQ/Euronext: MDXH) (?mdxhealth? or the ?Company?), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant?s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| August 2, 2022 |
Exhibit 99.1 NEWS RELEASE – INSIDE AND REGULATED INFORMATION August 2, 2022, 4:00PM EDT / 22:00 CET Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results ● Solidifies leadership in the precision diagnostics urology market ● Provides the most comprehensive menu of advanced molecular tests for urology in prostate cancer ● Enha |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 7 |
|
| May 27, 2022 |
Free English translation – for information purposes only Exhibit 3.1 Free English translation – for information purposes only MDxHealth Abbreviated: MDxH Public limited liability company (société anonyme) Registered office: 4040 Herstal, rue d’Abhooz 31, CAP Business Center, Zone Industrielle des Hauts-Sarts Company number: VAT BE 0479.292.440 COORDINATED ARTICLES OF ASSOCIATION AS AT MAY 25, 2022 Company incorporated by deed given before notary public |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant’s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 27, 2022 |
Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION 25 May 2022, 4:00 p.m. EDT / 22:00 CET MDxHealth Announces Results of its Annual and Extraordinary General Shareholders? Meetings and Resignation of Director IRVINE, CA, and HERSTAL, BELGIUM ? 25 May 2022 ? MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (?MDxHealth? or the ?Company?), a commercial-stage precision diagnostics company, today held |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number 001-40996 MDXHEALTH SA (Translation of registrant?s name into English) CAP Business Center Zone Industrielle des Hauts-Sarts 4040 Herstal, Belgium +32 4 257 70 2 |
|
| May 20, 2022 |
Exhibit 99.1 NEWS RELEASE - REGULATED INFORMATION May 19, 2022, 4:00PM EDT / 22:00 CET Palmetto GBA?s MolDX Issues Foundational LCD Covering the Indication for SelectMDx? for Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM ? May 19, 2022 ? ? MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial stage precision diagnostics company, announces that Palmetto GBA, a Medicare Administrative Contractor (MA |
|
| May 6, 2022 |
Exhibit 99.1 |
